CClinicalTrials.gg
RecruitingNCT07179016Updated Oct 1, 2025

Evaluating the Auricular Point Acupressure-Self Management Program for Chronic Musculoskeletal Pain Among Rural Populations

An interventional study of Auricular Point Acupressure (APA) - Self Management (SM) and Education Control in Chronic Pain (Back / Neck), Chronic Pain Management and Chronic Knee Pain, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year later.
Phase
Not applicable
Study type
Interventional
Enrollment
693
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The investigators will test an Auricular Point Acupressure Self-Management (APA-SM) program integrated into rural primary and specialty care and rural communities for chronic musculoskeletal pain (CMP). To maximize self-management of pain, the investigators developed a smartphone app which will allow the participants to learn to self-administer APA. The investigators will have 3 arms (APA-SM self-guided with remote training, APA-SM with in-person training, and Education Control) with 231 participants per arm (total=693 for 3 arms). The investigators will evaluate the clinical effectiveness of our 4-week APA-SM intervention compared to control in primary outcomes (pain intensity, pain interference, activity), secondary outcomes (HEAL Clinical Pain Core common data elements), and analgesic use up to 6 months follow-up.

Read the detailed description

The investigators integrated ecological momentary assessment into our app to measure real-world outcomes resulting in participants being able to self-monitor their progress, using this as an innovative behavior change strategy based on Bandura's self-efficacy, successfully initiating and maintaining behavior change. The primary endpoint will be immediate post-intervention with secondary endpoints at 1-month, 3-month, and 6-month follow-ups after the intervention. The investigators will also evaluate implementation outcomes and cost-effectiveness. Our long-term goal is to increase the access and scalability of evidence-based interventions while addressing pain care disparities for rural individuals with limited resources and/or endure long distances to specialty pain care. Study recruitment will be 3 1/2 to 4 years followed by data analysis.

02

Conditions studied

  • Chronic Pain (Back / Neck)
  • Chronic Pain Management
  • Chronic Knee Pain
  • Joint Pain

Keywords

  • Chronic Pain
  • Rural population
  • Self-management
  • Chronic musculoskeletal pain
  • Auricular point acupressure
03

In context

Chronic Pain

2,930 studies on the registry are indexed under Chronic Pain; 701 are open to participants now.

This study's planned enrollment of 693 is above the median of 60 across 2,161 interventional studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

The University of Texas Health Science Center, Houston is the lead sponsor of 880 studies on the registry; 209 are open to participants now.

Of its 170 completed or terminated interventional studies of FDA-regulated products, 140 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Receive any pain management for CMP (neck, back, shoulder, hands, hips, knees, feet)
  • Have CMP ≥ 4 on a scale of 0-10 that has persisted for at least 3 months or has resulted in pain on at least half the days in the past 6 months

Exclusion criteria

Exclusion Criteria:

  • Severe ear skin disorder (Diagnosed with conditions e.g., eczema, lupus with skin involvement) which often require medical intervention and severe allergy to tape
  • Inability or unwillingness to provide informed consent
  • Use of some type of hearing aid where size may obstruct seed placement
  • Not living in rural area
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
693 participants (estimated)

Study arms

  • Experimental
    Remote APA-SM Training

    APA-SM self-guided with remote training

    Behavioral: Auricular Point Acupressure (APA) - Self Management (SM)

  • Experimental
    In-person APA-SM Training

    APA-SM with in-person training

    Behavioral: Auricular Point Acupressure (APA) - Self Management (SM)

  • Active comparator
    Pain Education

    Education Control

    Behavioral: Education Control

Interventions

  • BehavioralAuricular Point Acupressure (APA) - Self Management (SM)

    APA is a noninvasive and needle-free pain management therapy based on the principles of acupuncture. The APA-SM intervention program is aimed to manage chronic musculoskeletal pain leveraging a mobile app containing APA videos and remote vs in-person guidance or coaching to practice APA based on APA study assignment.

  • BehavioralEducation Control

    Education Control group receive an app but the content will be specific to pain and self-management (no APA content) and they practice pain self-management skills (no APA practice).

06

What researchers measure

Primary outcomes

  1. Change in pain as assessed by the pain, enjoyment of life, general activity (PEG) survey

    This is a three-item questionnaire and each is scored from 0 (no pain) to 10(worst pain) for a maximum score of 30. Higher score indicating worse outcome

    Time frame: Baseline, post intervention (4 weeks after baseline), 1 month, 3 months, 6 months

Secondary outcomes

  1. Change in pain as assessed by the Pain Catastrophizing Scale (PCS6)

    This is a six-item questionnaire and each is scored from 0 (not at all) to 4 (all the time) for a maximum score of 24. Higher score indicating greater pain catastrophizing.

    Time frame: Baseline, post intervention (4 weeks after baseline)

  2. Change in fear-avoidance beliefs as assessed by the Fear-Avoidance Beliefs Questionnaire (FABQ)

    This is a 16-item questionnaire. Each item is scored from 0 (completely disagree) to 6 (completely agree) for a maximum score of 96. Higher score indicating greater fear-avoidance beliefs.

    Time frame: Baseline, post intervention (4 weeks after baseline)

  3. Change in depression as assessed by the Patient Health Questionnaire (PHQ2 )

    This is a two-item questionnaire and each is scored from 0 (not at all) to 3(nearly every day) for a maximum score of 6. Higher score indicating greater depression.

    Time frame: Baseline, post intervention (4 weeks after baseline)

  4. Change in anxiety as assessed by the Generalized Anxiety Disorder (GAD2)

    This is a two-item questionnaire and each is scored from 0 (not at all) to 3 (nearly every day) for a maximum score of 6. Higher score indicating more anxiety.

    Time frame: Baseline, post intervention (4 weeks after baseline)

  5. Change in severity of pain and its impact on functioning as assessed by the Brief Pain Inventory (BPI) Short From

    This consist of six-item questionnaire regarding pain severity and nine-item questionnaire regarding pain interference. Higher score indicates greater pain severity and interference.

    Time frame: Baseline, post intervention (4 weeks after baseline)

  6. Change in physical function as assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function short form 6b (SF6b)

    This is a six-item questionnaire and each is scored from 1 (unable to do) to 5 (without any difficulty) for a maximum score of 30. Higher score indicates better physical function.

    Time frame: Baseline, post intervention (4 weeks after baseline)

  7. Change in disability as assessed by the Roland Morris Disability Questionnaire (RMDQ)

    This is a 24-item questionnaire and each is scored 0 (no) or 1 (yes) for a maximum score of 24. Higher score indicates greater disability.

    Time frame: Baseline, post intervention (4 weeks after baseline)

  8. Change in sleep duration as assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) for Sleep 6a (+Sleep Duration)

    This is a six-item questionnaire and each is scored from 1 (very good) to 5 (very poor) for a maximum score of 30. Higher scores indicate worse sleep disturbance. It also includes an additional single item (+Sleep Duration) assessing hours and minutes of sleep per night. Higher values indicates longer sleep duration.

    Time frame: Baseline, post intervention (4 weeks after baseline)

  9. Change in pain self-efficacy influenced by pain as assessed by the Pain Self-Efficacy Questionnaire 2 item Short Form (PSEQ2)

    This is a two-item questionnaire and each is scored from 0 (not at all confident) to 6 (completely confident) for a maximum score of 12. Higher score indicating greater pain self-efficacy.

    Time frame: Baseline, post intervention (4 weeks after baseline)

  10. Change in substance use as assessed by the Tobacco, Alcohol, Prescription medication, and other Substance (TAPS1) Substance Use Screener

    This is a five-item questionnaire and each is scored from 0 (daily or almost daily) to 4 (never) for a maximum score of 20. Higher score indicates lower substance use.

    Time frame: Baseline, post intervention (4 weeks after baseline)

  11. Change in quality of life as assessed by the World Health Organization Quality of Life 2 item (WHOQOL-2)

    This is a two-item questionnaire and each is scored from 1 (very poor/dissatisfied) to 5 (very good/satisfied) for a maximum score of 10. Higher score indicating better quality of life.

    Time frame: Baseline, post intervention(4 weeks after baseline)

  12. Change in positive outlook as assessed by the Healing Encounters and Attitudes Lists (HEAL)

    This is a six-item questionnaire and each is scored from 1 (not at all) to 5 (very much) for a maximum score of 30. Higher score indicates greater positive outlook.

    Time frame: Baseline, post intervention(4 weeks after baseline)

  13. Change in treatment expectancy as assessed by the Healing Encounters and Attitudes Lists (HEAL)

    This is a six-item questionnaire and each is scored from 1 (not at all) to 5 (very much) for a maximum score of 30. Higher score indicates greater treatment expectancy.

    Time frame: Baseline, post intervention(4 weeks after baseline)

  14. Change in attitude towards complement alternative medicine (CAM) as assessed by the Healing Encounters and Attitudes Lists (HEAL)

    This is a six-item questionnaire and each is scored from 1 (not at all) to 5 (very much) for a maximum score of 30. Higher score indicates more positive attitude toward CAM.

    Time frame: Baseline, post intervention (4 weeks after baseline)

  15. Change in analgesics and opioid use as assessed by the Ecological Momentary Assessment (EMA) diary

    Daily self-reported analgesic and opioid use (type, dose, frequency) recorded via EMA diary

    Time frame: Baseline, post intervention (4 weeks after baseline)

07

Study locations

1 of 3 sites recruiting
  • University of South Carolina
    Columbia, South Carolina 29208, United States
    Recruiting
  • University of North Texas Health Science Center at Fort Worth
    Fort Worth, Texas 76107, United States
    Not yet recruiting
  • The University of Texas Health science Center at Houston
    Houston, Texas 77030, United States
    Not yet recruiting
08

References and documents

Publications

  • Kawi J, Bolin J, Wu H, Min J, Bora R, Pace S, Akpan IN, Lockman A, Nnaka T. Auricular Point Acupressure Self-Management (APA-SM) program for chronic musculoskeletal pain among rural populations: a protocol for a pragmatic, randomized controlled trial. BMJ Open. 2026 Jun 8;16(6):e117632. doi: 10.1136/bmjopen-2026-117632. PubMed 42259555 ↗

Individual participant data

Plan to share: No — We have a Data Management and Sharing Plan and will comply with the policy set forth by NIH.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07179016
Lead sponsor
The University of Texas Health Science Center, Houston
Responsible party
Jennifer Kawi (Distinguished Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Sep 17, 2025
Start date
Sep 11, 2025
Primary completion
Jun 30, 2029 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Oct 1, 2025

Study contacts

Jennifer Kawi, PhD, MSN, FNP-BC, CNE, FAAN
Contact
Jennifer.Kawi@uth.tmc.edu
713-500-2293
Jungkyung Min, PhD, MS, RN
Contact
Jungkyung.Min@uth.tmc.edu
979-450-2091
Jennifer Kawi, PhD, MSN, FNP-BC, CNE, FAAN
principal investigator · The University of Texas Health Science Center, Houston

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion